Goldman Sachs Upgrades Amylyx Pharma to Buy, Raises Price Target to $49
Portfolio Pulse from richadhand@benzinga.com
Goldman Sachs analyst Chris Shibutani has upgraded Amylyx Pharma (NASDAQ:AMLX) from Neutral to Buy and raised the price target from $45 to $49.
July 24, 2023 | 9:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amylyx Pharma has been upgraded from Neutral to Buy by Goldman Sachs, with a raised price target from $45 to $49.
The upgrade from Neutral to Buy by Goldman Sachs indicates a positive outlook for Amylyx Pharma. The raised price target from $45 to $49 suggests that the analyst believes the stock has potential for growth in the short term. This could lead to increased investor interest and potentially a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100